C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms

Stroke

Volumn 43, Issue 9, 2012, Pages 2457-2467

  Heydenreich, Nadine ^a   Nolte, Marc W ^b   Göb, Eva ^a   Langhauser, Friederike ^a   Hofmeister, Marion ^b   Kraft, Peter ^a   Albert Weissenberger, Christiane ^a   Brede, Marc ^a   Varallyay, Csanad ^a   Göbel, Kerstin ^c   Meuth, Sven G ^c   Nieswandt, Bernhard ^a,d   Dickneite, Gerhard ^b   Stoll, Guido ^a   Kleinschnitz, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CSL BEHRING GMBH   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

blood brain barrier; C1 inhibitor; inflammation; kallikrein kinin system; middle cerebral artery occlusion; thrombosis

Indexed keywords

BERINERT P; COMPLEMENT COMPONENT C1S INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN FUNCTION; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; FEMALE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; THROMBOGENESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN EDEMA; BRAIN ISCHEMIA; COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; FIBRINOLYTIC AGENTS; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL THROMBOSIS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; NEUROLOGIC EXAMINATION; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 84865600930     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.660340     Document Type: Article

References (44)

1. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808.
2. Magnus T, Wiendl H, Kleinschnitz C. Immune mechanisms of stroke. Curr Opin Neurol. 2012;25:334-340.
3. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2009;1788:842-857.
4. Ayata C, Ropper AH. Ischaemic brain oedema. J Clin Neurosci. 2002;9: 113-124.
5. Bardutzky J, Schwab S. Antiedema therapy in ischemic stroke. Stroke. 2007;38:3084-3094.
6. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008;112:3555-3562.
7. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203:513-518.
8. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycopro-tein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323-2330.
9. Pham M, Stoll G, Nieswandt B, Bendszus M, Kleinschnitz C. Blood coagulation factor XII-a neglected player in stroke pathophysiology. J Mol Med (Berl). 2012;90:119-126.
10. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol. 2011;589:4115-4123.
11. Maas C, Oschatz C, Renné T. The plasma contact system 2.0. Semin Thromb Hemost. 2011;37:375-381.
12. Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, Stoll G, et al. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke. 2009;40:285-293.
13. Müller F, Gailani D, Renné T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol. 2011;18:349-355.
14. Davis AE III, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol. 2008;45:4057-4063.
15. Horstick G, Heimann A, Götze O, Hafner G, Berg O, Böhmer P, et al. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation. 1997;95:701-708.
16. Lehmann TG, Heger M, Münch S, Kirschfink M, Klar E. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int. 2000;13: S547-S550.
17. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20: 84-91.
18. Kleinschnitz C, Blecharz K, Kahles T, Schwarz T, Kraft P, Göbel K, et al. Glucocorticoid insensitivity at the hypoxic blood-brain barrier can be reversed by inhibition of the proteasome. Stroke. 2011;42:1081-1089.
19. Longhi L, Perego C, Ortolano F, Zanier ER, Bianchi P, Stocchetti N, et al. C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice. Crit Care Med. 2009;37:659-665.
20. Storini C, Rossi E, Marrella V, Distaso M, Veerhuis R, Vergani C, et al. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis. 2005;19: 10-17.
21. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472-476.
22. Moran PM, Higgins LS, Cordell B, Moser PC. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc Natl Acad Sci U S A. 1995; 92:5341-5345.
23. Reglodi D, Tamás A, Lengvári I. Examination of sensorimotor performance following middle cerebral artery occlusion in rats. Brain Res Bull. 2003;59:459-466.
24. Kraft P, Schwarz T, Meijers JC, Stoll G, Kleinschnitz C. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS One. 2010;5:e11658.
25. Braeuninger S, Kleinschnitz C. Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems. Exp Transl Stroke Med. 2009;1:8.
26. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab. 2006;26:1465-1478.
27. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244-2250.
28. Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40:e50-e52.
29. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. 2010;8:e1000479.
30. Matsuo Y, Mihara Si, Ninomiya M, Fujimoto M. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke. 2001;32: 2143-2148.
31. Barone FC, Globus MY, Price WJ, White RF, Storer BL, Feuerstein GZ, et al. Endothelin levels increase in rat focal and global ischemia. J Cereb Blood Flow Metab. 1994;14:337-342.
32. Cai S, Davis AE III. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol. 2003;171:4786-4791.
33. Storini C, Bergamaschini L, Gesuete R, Rossi E, Maiocchi D, De Simoni MG. Selective inhibition of plasma kallikrein protects brain from reperfusion injury. J Pharmacol Exp Ther. 2006;318:849-854.
34. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation. 2010;121:1510-1517.
35. Stoll G, Kleinschnitz C, Nieswandt B. Combating innate inflammation: a new paradigm for acute treatment of stroke? Ann N Y Acad Sci. 2010; 1207:149-154.
36. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52:91-112.
37. Gesuete R, Storini C, Fantin A, Stravalaci M, Zanier ER, Orsini F, et al. Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol. 2009; 66:332-342.
38. De Simoni MG, Storini C, Barba M, Catapano L, Arabia AM, Rossi E, et al. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab. 2003;23:232-239.
39. Pham M, Kleinschnitz C, Helluy X, Bartsch AJ, Austinat M, Behr VC, et al. Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI. Neuroimage. 2010;49:2907-2914.
40. Banerji A. Current treatment of hereditary angioedema: An update on clinical studies. Allergy Asthma Proc. 2010;31:398-406.
41. Keating GM. Human C1-esterase inhibitor concentrate (Berinert). BioDrugs. 2009;23:399-406.
42. Dickneite G. Influence of C1-inhibitor on inflammation, edema and shock. Behring Inst Mitt. 1993;93:299-305.
43. De Simoni MG, Rossi E, Storini C, Pizzimenti S, Echart C, Bergam-aschini L. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am J Pathol. 2004; 164:1857-1863.
44. Wahl F, Allix M, Plotkine M, Boulu RG. Neurological and behavioral outcomes of focal cerebral ischemia in rats. Stroke. 1992;23:267-272.